Analysts Have Conflicting Sentiments on These Healthcare Companies: United Therapeutics (UTHR) and BioRestorative Therapies (BRTX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on United Therapeutics (UTHR – Research Report) and BioRestorative Therapies (BRTX – Research Report).

United Therapeutics (UTHR)

In a report released today, Chris Shibutani from Goldman Sachs maintained a Hold rating on United Therapeutics, with a price target of $240.00. The company’s shares closed last Thursday at $259.79, close to its 52-week high of $261.54.

According to TipRanks.com, Shibutani is a 5-star analyst with an average return of 12.4% and a 44.5% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Syndax Pharmaceuticals, and Revance Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for United Therapeutics with a $302.22 average price target.

See the top stocks recommended by analysts >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on UTHR:

• United Therapeutics reports Q1 EPS $6.17, consensus $5.65
• United Therapeutics Corp. (UTHR) Q1 Earnings Cheat Sheet
• Liquidia provides YUTREPIA regulatory update
• United Therapeutics Announces $1 Billion Stock Buyback Plan
• United Therapeutics announces $1B ASR program